ALPL and hypophosphatasia: Furthermore, treatment of HPP patients with a sclerostin antibody and the osteoporosis medication teriparatide have already been described, but these approaches primarily target bone mass and fracture healing rather than substituting or supporting TNAP activity [63,64,65,66,67,68,69].